Free Trial
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Arbutus Biopharma logo
$3.33 -0.02 (-0.60%)
As of 09:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Key Stats

Today's Range
$3.30
$3.40
50-Day Range
$3.09
$3.58
52-Week Range
$2.70
$4.72
Volume
456,725 shs
Average Volume
664,254 shs
Market Capitalization
$637.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Arbutus Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

ABUS MarketRank™: 

Arbutus Biopharma scored higher than 43% of companies evaluated by MarketBeat, and ranked 672nd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arbutus Biopharma has received no research coverage in the past 90 days.

  • Read more about Arbutus Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arbutus Biopharma is -8.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arbutus Biopharma is -8.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arbutus Biopharma has a P/B Ratio of 6.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arbutus Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    9.02% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 7.24%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arbutus Biopharma does not currently pay a dividend.

  • Dividend Growth

    Arbutus Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.02% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 7.24%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Arbutus Biopharma has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Arbutus Biopharma this week, compared to 3 articles on an average week.
  • Search Interest

    7 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arbutus Biopharma's insider trading history.
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

Arbutus Biopharma Corporation (ABUS) - Yahoo Finance
AI Frenzy Could Send ‘EarnPhone’ Soaring
The hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and searches — are feeding the next wave of AI innovation. Big Tech is harvesting it. Mode Mobile is giving it back to you. They are creating a user-powered data economy that shares the upside, and +50M users have already generated +$325M in earnings. This isn't a theory… Mode’s 32,481% revenue growth from 2019-2022 landed them the #1 spot on Deloitte’s 2023 list of fastest growing companies in software, and they’ve secured the Nasdaq ticker $MODE ahead of a potential IPO. The offering could close any moment now. AI breakthroughs are everywhere, but these models need your data to survive. Invest in the company that allows you to share in the profits from yours.
See More Headlines

ABUS Stock Analysis - Frequently Asked Questions

Arbutus Biopharma's stock was trading at $3.27 at the start of the year. Since then, ABUS shares have increased by 0.9% and is now trading at $3.30.

Arbutus Biopharma Corporation (NASDAQ:ABUS) announced its quarterly earnings results on Wednesday, May, 14th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.04. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $2.54 million. Arbutus Biopharma had a negative net margin of 1,196.64% and a negative trailing twelve-month return on equity of 75.51%.

Top institutional investors of Arbutus Biopharma include Aberdeen Group plc (0.51%), Assenagon Asset Management S.A. (0.02%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.02%).
View institutional ownership trends
.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/14/2025
Today
7/30/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABUS
CIK
1447028
Employees
90
Year Founded
1992

Price Target and Rating

High Price Target
$7.00
Low Price Target
$5.00
Potential Upside/Downside
+65.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.92 million
Net Margins
-1,196.64%
Pretax Margin
-1,195.86%
Return on Equity
-75.51%
Return on Assets
-55.81%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
6.01
Quick Ratio
6.01

Sales & Book Value

Annual Sales
$6.17 million
Price / Sales
103.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
6.53

Miscellaneous

Outstanding Shares
191,530,000
Free Float
152,647,000
Market Cap
$637.79 million
Optionable
Optionable
Beta
1.20

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ABUS) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners